NCT00713401View on ClinicalTrials.gov

Safety Study of Tecadenoson to Treat Atrial Fibrillation

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

April 30, 2008

Study Completion Date

July 31, 2008

Conditions
Atrial Fibrillation
Interventions
DRUG

Tecadenoson

Tecadenoson administered intravenously (i.v.)

DRUG

Esmolol

Esmolol low dose infusion according to manufacturer's instructions

Trial Locations (1)

94304

CV Therapeutics, Inc., Palo Alto

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY